已传文件：photo/1770282139.png
Surgery is the preferred treatment option for most solid tumors, but the residual metastatic cancer cells after surgery often lead to tumor recurrence and patient death, which has long been a challenge for clinical treatment. Recently, Professor Kong Lingyi from China Pharmaceutical University and Researcher Zhang Chao from his team published a significant study in "Nature Nanotechnology", developing a biomimetic vesicle nanovaccine based on tumor cell modification, providing a new direction for personalized immunotherapy of postoperative metastatic cancer!
Key analysis
Core discovery: The STX11 protein endows tumor cells with "immune presentation ability".
The research team first discovered that the Syntaxin 11 (STX11) protein highly expressed in immune cells is extremely low in tumor cells. And it is precisely this protein that can significantly enhance the expression of MHC I molecules and co-stimulatory molecules CD80/CD86 on the tumor cell membrane, allowing tumor cells to acquire the antigen-presenting function of dendritic cells (DC). This discovery broke the traditional perception and laid the foundation for the "immune modification" of tumor cells.
Further research confirmed that high expression of STX11 is associated with improved overall survival in patients with metastatic breast cancer and melanoma, and in breast cancer tissues, STX11 expression is positively correlated with the levels of MHC I and CD80/CD86, suggesting its key role in tumor immunity.
Vaccine preparation: From patient tumor tissue to personalized nanovaccine
Based on the functional discovery of STX11, the research team designed a set of efficient personalized vaccine preparation process Original link: https://www.nature.com/articles/s41565-025-02113-w
